Maria Babak, Head of The Babak Lab and Assistant Professor at City University of Hong Kong, shared The Babak Lab’s post on LinkedIn, adding:
“Exciting to see the phase II results for the cabozantinib–temozolomide combination, which achieved a 74% 12-week PFS rate in advanced leiomyosarcoma.”
Quoting The Babak Lab’s post:
“Clinical Mondays: Cabozantinib + Temozolomide in Advanced Leiomyosarcoma
A new paper in The Lancet Oncology reports results of a phase II study testing the combination of cabozantinib (a multi-kinase inhibitor targeting VEGFR/MET) with temozolomide (chemotherapy) in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.
Key Focus
The study investigated dual targeting of VEGF/MET signaling together with DNA damage as a treatment strategy for leiomyosarcoma.
Key Insights
- Median PFS: 6.3 months
- Median OS: 19.2 months
- ORR: 17%
- Toxicity was manageable, with no new safety signals
Conclusion
Cabozantinib plus temozolomide shows clinically meaningful disease control in advanced leiomyosarcoma and warrants further testing in randomized trials.”
Title: Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
Authors: Varun Monga, Scott Okuno, Prof Brian Van Tine, Prof Seth M Pollack, Mia Weiss, Angela Hirbe, Pedro Viveiros, Brian Schulte, Steven Attia, Brittany Siontis, Prof Mohammad M Milhem, John A Charlson, Steven Robinson, Oluwatimilehin Okunowo, Paul Frankel, Doni Woo, Janet Yoon, Mark Agulnik
Read the Full Article.
More posts featuring Maria (Masha) Babak and The Babak Lab.
